Bacterial News and Research

RSS

New protein fragments identified for anthrax vaccine development

Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine.

4 Sep 2009

Strata brands of Foley catheters launched by Rochester Medical Corporation

Rochester Medical Corporation (Nasdaq: ROCM) today announced the introduction of its Strata brands of Foley catheters. This new Foley product line features proprietary comfort layered technology. The company's StrataSI(TM) catheter is all-silicone, while the StrataNF(TM) version includes a nitrofurazone anti-infective matrix within the silicone.

4 Sep 2009

Giant Eagle offers generic prescription antibiotics for free at its in-store pharmacies

At a time when many families affected by a difficult economy are struggling with the costs of prescription medications, supermarket retailer Giant Eagle, Inc. is making ten broadly used generic prescription antibiotics in 46 common dosages available for free every day at all of its 210 in-store pharmacies.

4 Sep 2009

New center to study mathematical modeling of drug resistance and internention to be established at HSPH

A new center that will focus on mathematical modeling of drug resistance, seasonal infectious diseases, and intervention allocation will be established at the Harvard School of Public Health (HSPH).

4 Sep 2009

Sheller, P.C helps to settle the largest whistleblower complaint

Pfizer Inc. ignored a 2005 FDA Warning Letter to stop promoting its antibiotic Zyvox(R) as clinically superior to the significantly less expensive, generic vancomycin when its own FDA-approved label indicated otherwise. The drug giant also defrauded federal and state taxpayers by marketing Zyvox off-label, according to a qui tam whistleblower complaint filed by Philadelphia law firm Sheller, P.C. and other documents unsealed with today's $2.3 billion Pfizer settlement.

3 Sep 2009

Kane Biotech announces Harvard Medical School's research publication on its DispersinB product

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce a recent research publication by Harvard Medical School on their finding of DispersinB® enzyme specific substrate in Acinetobacter baumannii (A. baumannii).

3 Sep 2009

Thermo Fisher Scientific to acquire B.R.A.H.M.S. for $470 million

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has signed a definitive agreement to acquire B.R.A.H.M.S. AG for €330 million (approximately $470 million USD). B.R.A.H.M.S. is a leading provider of specialty in-vitro diagnostic tests based on its patented biomarkers for sepsis, cardiovascular and pulmonary diseases, as well as intensive care treatments and prenatal screening.

From Thermo Fisher Scientific Inc. 3 Sep 2009

NIH grants $8 million to Fox Chase Cancer Center for cancer research

The Fox Chase Cancer Center has received an $8 million grant from the National Center for Research Resources of the National Institutes of Health (NCRR/NIH) to expand their laboratory animal research facility. The new facility will support advanced research into the fundamental biological processes underlying cancer, opening the way for the development of new treatments. The funds for the grant were made available through the American Recovery and Reinvestment Act.

3 Sep 2009

Preliminary lab results of SHBAN hand sanitizer solution announced

BioTech Medics, Inc. (PINKSHEETS: BMCS) announces that it has received preliminary independent clinical testing of its patented SHBAN™ Hand Sanitizer Solution to demonstrate it kills the H1N1 (Swine) Influenza A virus.

3 Sep 2009

Arrayit receives patent certification from China

Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, announces that on August 31st, 2009 the company received a patent certificate from the most populous country on the planet, the People's Republic of China. The patent covers Dr. Mark Schena's microarray methods of genotyping multiple patient samples, commonly referred to as Arrayit's "Variation Identification Platform™" (VIP) technology.

2 Sep 2009

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluoroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

2 Sep 2009

Pathogenic microbes can suppress immune system in newborns

Group B Streptococcus (GBS), a bacterial pathogen that causes sepsis and meningitis in newborn infants, is able to shut down immune cell function in order to promote its own survival, according to researchers at the University of California, San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

2 Sep 2009

Eye disease medication lowers death rate among Ethiopian children

Children in Ethiopia who received the antibiotic azithromycin as a method for controlling the contagious eye disease trachoma had a lower odds of death compared to children who did not receive the antibiotic, according to a study in the September 2 issue of JAMA.

2 Sep 2009

Seeplex FluA ACE subtyping test enables simultaneous detection of four major influenza A subtypes

Seegene today released a new influenza A sub-type screening test, Seeplex FluA ACE Subtyping, that enables simultaneous detection of pandemic novel influenza A (H1N1), seasonal human influenza A H1, seasonal human influenza A H3 and avian influenza A H5 in a single reaction.

1 Sep 2009

OHSU study reveals that fluoroquinolones may cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

1 Sep 2009

Antibiotic functioning as an off switch being developed for gene therapy of Parkinson's disease

A common antibiotic can function as an "off switch" for a gene therapy being developed for Parkinson's disease, according to University of Florida researchers writing online in advance of September's Molecular Therapy.

29 Aug 2009

NAT gains importance as traditional testing methods become inadequate

An expanding population of bacterial strains that are drug resistant, including methicillin-resistant Staphylococcus aureus (MRSA), will be the most important justification for nucleic acid-based tests (NAT).

28 Aug 2009

Polymedix And UMass receive Phase I STTR contract for research on drug-resistant bacteria treatments

PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, have received a Phase I Small Business Technology Transfer (STTR) contract in the amount of $100,000 to support research to identify lead antimicrobial compounds to effectively treat multi-drug resistant and biofilm-embedded bacteria.

28 Aug 2009

Enzymes could be targeted to kill dangerous pathogens

Researchers at Burnham Institute for Medical Research (Burnham), University of Texas Southwestern Medical Center and University of Maryland have demonstrated that an enzyme that is essential to many bacteria can be targeted to kill dangerous pathogens.

28 Aug 2009

USPTO awards two new patents to Nerites

Nerites Corporation announced Thursday that the United States Patent and Trademark Office (USPTO) issued two new patents covering the company’s technology. These “composition of matter” patents provide underlying intellectual property protection for surgical adhesives, films, and coatings. Nerites’ scientists create synthetic mimetics of the protein components used by marine mussels to stick to rocks under water.

28 Aug 2009

Bacterial News and Research

New protein fragments identified for anthrax vaccine development

Strata brands of Foley catheters launched by Rochester Medical Corporation

Giant Eagle offers generic prescription antibiotics for free at its in-store pharmacies

New center to study mathematical modeling of drug resistance and internention to be established at HSPH

Sheller, P.C helps to settle the largest whistleblower complaint

Kane Biotech announces Harvard Medical School's research publication on its DispersinB product

Thermo Fisher Scientific to acquire B.R.A.H.M.S. for $470 million

NIH grants $8 million to Fox Chase Cancer Center for cancer research

Preliminary lab results of SHBAN hand sanitizer solution announced

Arrayit receives patent certification from China

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Pathogenic microbes can suppress immune system in newborns

Eye disease medication lowers death rate among Ethiopian children

Seeplex FluA ACE subtyping test enables simultaneous detection of four major influenza A subtypes

OHSU study reveals that fluoroquinolones may cause double vision

Antibiotic functioning as an off switch being developed for gene therapy of Parkinson's disease

NAT gains importance as traditional testing methods become inadequate

Polymedix And UMass receive Phase I STTR contract for research on drug-resistant bacteria treatments

Enzymes could be targeted to kill dangerous pathogens

USPTO awards two new patents to Nerites

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News